Aldo Trylesinski

2.1k total citations
44 papers, 926 citations indexed

About

Aldo Trylesinski is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Aldo Trylesinski has authored 44 papers receiving a total of 926 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Epidemiology, 23 papers in Hepatology and 17 papers in Infectious Diseases. Recurrent topics in Aldo Trylesinski's work include Hepatitis C virus research (22 papers), Hepatitis B Virus Studies (21 papers) and Liver Disease Diagnosis and Treatment (18 papers). Aldo Trylesinski is often cited by papers focused on Hepatitis C virus research (22 papers), Hepatitis B Virus Studies (21 papers) and Liver Disease Diagnosis and Treatment (18 papers). Aldo Trylesinski collaborates with scholars based in France, United States and Switzerland. Aldo Trylesinski's co-authors include Edward Gane, Christine Katlama, Isabelle Pellegrin, Hervé Fleury, Henry Lik‐Yuen Chan, Yves Benhamou, Willy Rozenbaum, Gwénaël Le Teuff, Renaud Urbinelli and Christophe Piketty and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and PLoS ONE.

In The Last Decade

Aldo Trylesinski

44 papers receiving 897 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aldo Trylesinski France	15	696	560	309	190	63	44	926
Míriam Romero Spain	19	787 1.1×	844 1.5×	324 1.0×	47 0.2×	18 0.3×	55	1.1k
Inmaculada Jiménez-Nàcher Spain	9	235 0.3×	265 0.5×	246 0.8×	86 0.5×	24 0.4×	19	471
M Steuerwald Switzerland	9	390 0.6×	161 0.3×	84 0.3×	97 0.5×	162 2.6×	16	550
Teresa Aldámiz‐Echevarría Spain	13	277 0.4×	223 0.4×	125 0.4×	97 0.5×	15 0.2×	47	483
Hugo Fainboim Argentina	22	1.1k 1.6×	1.2k 2.1×	199 0.6×	28 0.1×	46 0.7×	54	1.4k
J.L. Moya Spain	7	340 0.5×	377 0.7×	93 0.3×	25 0.1×	17 0.3×	9	514
Cristina Díez Spain	13	225 0.3×	167 0.3×	92 0.3×	64 0.3×	11 0.2×	58	396
P. Wantzin Denmark	13	513 0.7×	537 1.0×	98 0.3×	21 0.1×	30 0.5×	26	671
Roger Trinh United States	13	886 1.3×	1.0k 1.8×	420 1.4×	125 0.7×	7 0.1×	38	1.2k
C. De Bac Italy	11	421 0.6×	424 0.8×	108 0.3×	28 0.1×	10 0.2×	27	542

Countries citing papers authored by Aldo Trylesinski

Since Specialization

Citations

This map shows the geographic impact of Aldo Trylesinski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aldo Trylesinski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aldo Trylesinski more than expected).

Fields of papers citing papers by Aldo Trylesinski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aldo Trylesinski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aldo Trylesinski. The network helps show where Aldo Trylesinski may publish in the future.

Co-authorship network of co-authors of Aldo Trylesinski

This figure shows the co-authorship network connecting the top 25 collaborators of Aldo Trylesinski. A scholar is included among the top collaborators of Aldo Trylesinski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aldo Trylesinski. Aldo Trylesinski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rinella, Mary E., Jean‐François Dufour, Quentin M. Anstee, et al.. (2021). Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. Journal of Hepatology. 76(3). 536–548. 122 indexed citations

Piratvisuth, Teerha, et al.. (2016). Comprehensive review of telbivudine in pregnant women with chronic hepatitis B. World Journal of Hepatology. 8(9). 452–452. 12 indexed citations

Piratvisuth, Teerha, Piyawat Komolmit, Henry C. B. Chan, et al.. (2016). Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy. Drugs in Context. 5. 1–9. 2 indexed citations

Hou, Jinlin, Guangfeng Shi, Mobin Wan, et al.. (2015). Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B. Advances in Therapy. 32(8). 727–741. 18 indexed citations

Marcellin, Patrick, Karsten Wursthorn, Heiner Wedemeyer, et al.. (2014). Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. Journal of Hepatology. 62(1). 41–47. 41 indexed citations

Leung, Nancy W.Y., Eva Herrmann, George Lau, et al.. (2014). Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B. Infectious Diseases and Therapy. 3(2). 191–202. 7 indexed citations

Thongsawat, Satawat, Edward Gane, Yun‐Fan Liaw, et al.. (2012). Efficacy and safety of continuous 4‐year telbivudine treatment in patients with chronic hepatitis B. Journal of Viral Hepatitis. 20(4). e37–46. 63 indexed citations

Chan, Henry Lik‐Yuen, Edward Gane, Shiv Kumar Sarin, et al.. (2012). Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment‐naïve patients with HBV‐related decompensated cirrhosis. Journal of Viral Hepatitis. 19(10). 732–743. 79 indexed citations

Hou, Jiajie, Dong Xu, Zachary Goodman, et al.. (2011). 716 FIVE-YEAR TELBIVUDINE TREATMENT WITH EFFECTIVE VIRAL SUPPRESSION RESULTS IN RESOLUTION OF LIVER INFLAMMATION AND FIBROSIS REGRESSION IN PATIENTS WITH CHRONIC HEPATITIS B. Journal of Hepatology. 54. S287–S287. 5 indexed citations

10.

Ahn, Sang Hoon, Young Oh Kweon, Seung Woon Paik, et al.. (2011). Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. Hepatology International. 6(4). 696–706. 5 indexed citations

11.

Gane, Edward, Henry Lik‐Yuen Chan, G Choudhuri, et al.. (2010). 7 TREATMENT OF DECOMPENSATED HBV-CIRRHOSIS: RESULTS FROM 2-YEARS RANDOMIZED TRIAL WITH TELBIVUDINE OR LAMIVUDINE. Journal of Hepatology. 52. S4–S4. 13 indexed citations

12.

Zoulim, Fabien, Parviz Parvaz, Patrick Marcellin, et al.. (2009). Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. Liver International. 29(3). 420–426. 11 indexed citations

13.

Girard, Pierre Marie, André Cabié, C. Michelet, et al.. (2009). A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients. Journal of Antimicrobial Chemotherapy. 64(1). 126–134. 12 indexed citations

14.

Lacombe, Karine, Alan Boyd, Jean‐Michel Molina, et al.. (2008). 694 MDRD CREATININE CLEARANCE IS NOT ALTERED IN HIV-HBV CO-INFECTED PATIENTS WITH A NORMAL RENAL FUNCTION AND TREATED WITH TENOFOVIR (TDF). Journal of Hepatology. 48. S259–S259. 2 indexed citations

15.

Benhamou, Yves, Hervé Fleury, Pascale Trimoulet, et al.. (2006). Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology. 43(3). 548–555. 121 indexed citations

16.

Dominguez, Stéphanie, Jade Ghosn, Gilles Peytavin, et al.. (2006). Efficacy and safety of tenofovir double‐dose in treatment‐experienced HIV‐infected patients: The tenoplus study. Journal of Medical Virology. 79(2). 105–110. 4 indexed citations

17.

Landman, Roland, Diane Descamps, Gilles Peytavin, et al.. (2005). Early Virologic Failure and Rescue Therapy of Tenofovir, Abacavir, and Lamivudine for Initial Treatment of HIV-1 Infection: TONUS Study. HIV Clinical Trials. 6(6). 291–301. 33 indexed citations

18.

Katlama, Christine, D. Lacoste, C. Aquilina, et al.. (2001). MIKADO: a multicentre, open‐label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine. HIV Medicine. 2(1). 20–26. 4 indexed citations

19.

Pellegrin, Isabelle, Dominique Breilh, P. Mercié, et al.. (2001). Pharmacokinetics and Resistance Mutations Affect Virologic Response to Ritonavir/Saquinavir-Containing Regimens. Therapeutic Drug Monitoring. 23(4). 332–340. 18 indexed citations

20.

Demoly, Pascal, D. Messaad, Aldo Trylesinski, et al.. (1998). Nelfinavir-induced urticaria and successful desensitization. Journal of Allergy and Clinical Immunology. 102(5). 875–876. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact